Experimental drug aims to heal damaged lung arteries

NCT ID NCT07487441

Not yet recruiting Disease control Sponsor: Franz Rischard, DO Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study will test whether the drug sotatercept can reverse damage to the lung's blood vessels in people with pulmonary arterial hypertension (PAH). Researchers will use special imaging techniques to look inside the arteries and see if they become healthier over 9 months. The study plans to enroll 30 adults with PAH.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: sotatercept
What this could lead to: If it works, this could point toward a treatment that reverses lung artery damage in pulmonary hypertension, potentially improving blood flow and symptoms.
What could go wrong: This is a small, early-stage study with only 30 participants. It is not yet recruiting, and the main goal is to see if the drug changes blood vessel structure, not to prove it improves outcomes. There may be risks from the imaging procedures.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PULMONARY ARTERIAL HYPERTENSION (PAH) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pulmonary arterial hypertension pulmonary hypertension

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PULMONARY ARTERIAL HYPERTENSION (PAH) PULMONARY HYPERTENSION

Contacts and locations

Locations

The Clinical and Translational Sciences Research Center

Tucson, Arizona, 85724, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.